Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by ALX Oncology ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update May 09, 2024 From ALX Oncology Via GlobeNewswire Tickers ALXO ALX Oncology Appoints Allison Dillon as Chief Business Officer May 07, 2024 From ALX Oncology Via GlobeNewswire Tickers ALXO ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer April 30, 2024 From ALX Oncology Via GlobeNewswire Tickers ALXO ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting April 24, 2024 From ALX Oncology Via GlobeNewswire Tickers ALXO ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”) April 09, 2024 From ALX Oncology Via GlobeNewswire Tickers ALXO ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update March 07, 2024 From ALX Oncology Via GlobeNewswire Tickers ALXO ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting March 05, 2024 From ALX Oncology Via GlobeNewswire Tickers ALXO ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 03, 2024 From ALX Oncology Via GlobeNewswire Tickers ALXO ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update November 13, 2023 From ALX Oncology Via GlobeNewswire Tickers ALXO ALX Oncology Announces November Investor Conference Participation November 01, 2023 From ALX Oncology Via GlobeNewswire Tickers ALXO ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares October 10, 2023 From ALX Oncology Via GlobeNewswire Tickers ALXO ALX Oncology Announces Pricing of Public Offering October 05, 2023 From ALX Oncology Via GlobeNewswire Tickers ALXO ALX Oncology Announces Proposed Public Offering October 04, 2023 From ALX Oncology Via GlobeNewswire Tickers ALXO ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer October 03, 2023 From ALX Oncology Via GlobeNewswire Tickers ALXO ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer October 02, 2023 From ALX Oncology Via GlobeNewswire Tickers ALXO ALX Oncology Realigns Executive Leadership Team September 06, 2023 From ALX Oncology Via GlobeNewswire Tickers ALXO ALX Oncology Announces September Investor Conference Participation August 31, 2023 From ALX Oncology Via GlobeNewswire Tickers ALXO ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update August 10, 2023 From ALX Oncology Via GlobeNewswire Tickers ALXO ALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric Cancer June 26, 2023 From ALX Oncology Via GlobeNewswire Tickers ALXO ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights May 11, 2023 From ALX Oncology Via GlobeNewswire Tickers ALXO ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian Cancer May 09, 2023 From ALX Oncology Via GlobeNewswire Tickers ALXO ALX Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma April 25, 2023 From ALX Oncology Via GlobeNewswire Tickers ALXO ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer March 13, 2023 From ALX Oncology Via GlobeNewswire Tickers ALXO ALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones March 09, 2023 From ALX Oncology Via GlobeNewswire Tickers ALXO ALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer February 16, 2023 From ALX Oncology Via GlobeNewswire Tickers ALXO ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2023 January 05, 2023 From ALX Oncology Via GlobeNewswire Tickers ALXO ALX Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference January 03, 2023 From ALX Oncology Via GlobeNewswire Tickers ALXO ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia December 12, 2022 From ALX Oncology Via GlobeNewswire Tickers ALXO ALX Oncology Appoints Scott Garland to its Board of Directors November 29, 2022 From ALX Oncology Via GlobeNewswire Tickers ALXO ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights November 08, 2022 From ALX Oncology Via GlobeNewswire Tickers ALXO Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.